圣湘生物(688289) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥1,238,871,704.01, representing a decrease of 17.70% compared to the same period last year[9] - The net profit attributable to shareholders for Q3 2021 was ¥636,245,663.83, down 18.54% year-over-year[9] - The basic earnings per share for Q3 2021 were ¥1.59, a decrease of 23.92% compared to the same period last year[13] - Total operating revenue for the first three quarters of 2021 was CNY 3,267,195,316.27, a decrease of 9.4% compared to CNY 3,605,270,884.58 in the same period of 2020[33] - The net profit for the first three quarters of 2021 was CNY 2,057,325,453.84, compared to CNY 2,365,642,378.51 in the same period of 2020, indicating a decrease of 13.0%[33] - The net profit attributable to the parent company's shareholders for the current period is ¥1,757,137,173.16, a decrease from ¥2,012,815,337.70 in the previous period, representing a decline of approximately 12.6%[35] - The total comprehensive income attributable to the parent company's owners is ¥1,769,200,251.54, down from ¥2,012,802,180.28, indicating a decrease of about 12.1%[39] - Basic and diluted earnings per share for the current period are both ¥4.39, compared to ¥5.52 in the previous period, reflecting a decrease of approximately 20.5%[39] Research and Development - The R&D investment totaled ¥38,820,764.98 in Q3 2021, an increase of 15.95% compared to the same period last year, accounting for 3.13% of revenue[13] - Research and development expenses increased to CNY 91,242,557.34 in 2021 from CNY 62,987,590.54 in 2020, reflecting a growth of 45.0%[33] Assets and Equity - The total assets at the end of Q3 2021 were ¥7,069,507,884.92, reflecting a 29.61% increase from the end of the previous year[13] - The company's total assets as of September 30, 2021, were CNY 7,069,507,884.92, up from CNY 5,454,374,137.67 at the end of 2020, representing a growth of 29.5%[30] - The total equity attributable to shareholders at the end of Q3 2021 was ¥6,364,625,274.26, an increase of 34.12% compared to the end of the previous year[13] - The company’s equity attributable to shareholders increased to CNY 6,364,625,274.26 as of September 30, 2021, from CNY 4,745,425,022.72 at the end of 2020, reflecting a growth of 34.1%[30] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥1,431,898,962.62, down 18.54% year-over-year[13] - Cash inflow from operating activities totaled ¥3,308,039,230.75, an increase from ¥3,206,948,248.51, showing a growth of about 3.2%[39] - Cash outflow from operating activities was ¥1,876,140,268.13, compared to ¥1,449,198,169.32 in the previous period, representing an increase of approximately 29.5%[39] - The net cash flow from operating activities is ¥1,431,898,962.62, down from ¥1,757,750,079.19, indicating a decline of about 18.5%[39] - Cash inflow from investment activities reached ¥3,988,910,931.02, significantly higher than ¥737,484,122.82 in the previous period, marking an increase of approximately 441.5%[40] - Cash outflow from investment activities was ¥5,417,348,095.04, compared to ¥3,676,640,544.09, reflecting an increase of about 47.2%[40] - The net cash flow from investment activities is -¥1,428,437,164.02, an improvement from -¥2,939,156,421.27 in the previous period, indicating a reduction in losses[40] Liabilities - The total liabilities as of September 30, 2021, were CNY 704,882,610.66, slightly down from CNY 708,949,114.95 at the end of 2020[30] Shareholder Information - The top shareholder, Dai Lizhong, holds 31.62% of the shares, with a total of 126,488,642 shares[20]